|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,216,183
US Patent 9,216,183, titled "Method of treating or preventing disease states involving lipid oxidation," was issued on December 22, 2015, to Northwestern University. The patent claims methods for treating or preventing disease states associated with lipid oxidation using compounds that inhibit or reduce such oxidation. Specifically, the patent focuses on therapies involving the administration of liproxstatin-1 and its analogs.
What is the Core Technology Claimed in US Patent 9,216,183?
The central innovation patented is a method of treating or preventing diseases characterized by lipid oxidation. This process involves administering a therapeutically effective amount of liproxstatin-1 or a functional analog. The claims define what constitutes a functional analog and the specific disease states targeted.
Key Components of the Claims:
- Active Agent: Liproxstatin-1 or a compound that inhibits lipid oxidation through a similar mechanism. The patent provides specific structural definitions for liproxstatin-1 and its analogs.
- Therapeutic Goal: Inhibition or reduction of lipid oxidation.
- Targeted Diseases: A broad spectrum of conditions linked to oxidative stress and lipid peroxidation, including cardiovascular diseases, neurodegenerative disorders, inflammatory conditions, and metabolic syndromes.
The patent's claims are structured to encompass a method of use, specifying the administration of the compound to a subject in need thereof. This structure provides broad protection for the therapeutic application of liproxstatin-1 and related molecules in treating a range of oxidative stress-related pathologies.
What are the Specific Disease States Covered by the Patent?
US Patent 9,216,183 broadly covers disease states involving lipid oxidation. This encompasses a wide array of conditions where the uncontrolled peroxidation of lipids plays a significant role in disease pathogenesis.
Identified Disease Categories:
- Cardiovascular Diseases: This includes conditions such as atherosclerosis, myocardial infarction, stroke, and hypertension, all of which have been linked to lipid oxidation and subsequent endothelial dysfunction.
- Neurodegenerative Disorders: Diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) are characterized by neuronal damage, where lipid peroxidation contributes to oxidative stress and neuronal death.
- Inflammatory Conditions: Chronic inflammatory diseases, including arthritis, inflammatory bowel disease, and sepsis, involve an increased burden of reactive oxygen species and lipid peroxidation, exacerbating tissue damage.
- Metabolic Disorders: Conditions such as diabetes mellitus (Type 1 and Type 2), obesity, and metabolic syndrome are associated with increased oxidative stress and dysregulation of lipid metabolism, making them potential targets for liproxstatin-1 therapy.
- Other Conditions: The patent also broadly references "disease states involving lipid oxidation," which could extend to certain cancers, aging-related diseases, and organ damage from ischemia-reperfusion injury.
The breadth of these disease categories signifies the potential applicability of the patented technology across multiple therapeutic areas where lipid oxidation is a contributing factor.
What are the Key Chemical Structures or Compounds Mentioned?
The patent's claims are centered around the compound liproxstatin-1 and its functional analogs. The definition of these analogs is crucial for understanding the scope of the patent.
Liproxstatin-1 and Analogs:
- Liproxstatin-1: The specific chemical entity named in the patent. Its structure is defined within the patent document, providing a precise molecular target.
- Functional Analogs: Compounds that exhibit similar biological activity to liproxstatin-1, specifically by inhibiting or reducing lipid oxidation. The patent defines these analogs by their mechanism of action and structural characteristics that enable this function. This includes compounds that:
- Possess an aminoxyl radical moiety.
- Are capable of scavenging peroxyl radicals.
- Are structurally related to liproxstatin-1, implying a shared pharmacophore responsible for antioxidant activity.
The patent provides examples and general formulas to delineate the scope of these analogs, ensuring protection for compounds that operate through a similar mechanism of lipid oxidation inhibition, even if their precise chemical structures vary. This broad definition aims to capture a range of related molecules with therapeutic potential.
What is the Mechanism of Action of the Patented Compounds?
The therapeutic benefit described in US Patent 9,216,183 stems from the compounds' ability to inhibit or reduce lipid oxidation. This process is a critical pathway in cellular damage and disease progression.
Mechanism of Lipid Oxidation Inhibition:
- Peroxyl Radical Scavenging: The primary mechanism involves the compounds acting as antioxidants. They scavenge reactive oxygen species (ROS), particularly peroxyl radicals (ROO•), which are key intermediates in the chain reaction of lipid peroxidation.
- Chain Breaking: Lipid peroxidation is a self-propagating chain reaction. By intercepting and neutralizing peroxyl radicals, liproxstatin-1 and its analogs break this chain, preventing further propagation of oxidative damage to cell membranes and other lipids.
- Stabilization of Lipid Membranes: By reducing lipid peroxidation, the compounds help maintain the integrity and fluidity of cell membranes, which are composed of lipids. Damaged lipid membranes can lead to cellular dysfunction and death.
- Modulation of Oxidative Stress Pathways: The inhibition of lipid oxidation indirectly influences other cellular pathways involved in oxidative stress and inflammation, contributing to a broader protective effect.
The patent emphasizes that the efficacy of these compounds is directly tied to their capacity to interfere with the process of lipid peroxidation, thereby mitigating cellular and tissue damage associated with various diseases.
What is the Patent Landscape for Lipid Oxidation Inhibitors?
The patent landscape for lipid oxidation inhibitors is diverse, reflecting the broad relevance of oxidative stress in human health and disease. US Patent 9,216,183 occupies a specific niche within this landscape, focusing on liproxstatin-1 and its analogs for a defined set of indications.
Key Aspects of the Landscape:
- Broad Antioxidant Patents: Numerous patents exist for various classes of antioxidants, including Vitamin E analogs, synthetic radical scavengers, and natural polyphenols. These patents may cover composition of matter, formulations, and general methods of use.
- Targeted Mechanism Patents: Some patents focus on specific mechanisms of ROS generation or specific enzymes involved in oxidative stress, such as NADPH oxidases or cyclooxygenase-2 (COX-2) inhibitors with antioxidant properties.
- Disease-Specific Patents: Many patents claim antioxidant compounds for the treatment of specific diseases where oxidative stress is a known factor. For example, patents exist for antioxidants in cardiovascular disease, neurodegenerative diseases, and cancer therapy.
- Liproxstatin-1 Related Patents: US Patent 9,216,183 is a key patent for liproxstatin-1 as a method of treatment. Related patents might cover the synthesis of liproxstatin-1, its specific formulations, or its use in combination therapies.
- Competitive Landscape: Competitors may hold patents on:
- Different classes of lipid oxidation inhibitors with alternative mechanisms.
- Analogous compounds to liproxstatin-1 that may or may not fall under the scope of this patent's claims.
- Patents for the treatment of the same disease indications using entirely different therapeutic approaches.
The strength of US Patent 9,216,183 lies in its specific claims regarding the method of treating disease states involving lipid oxidation using liproxstatin-1 and its defined analogs. Companies developing similar therapies must carefully navigate this patent landscape to avoid infringement.
What is the Status and Expiration Date of US Patent 9,216,183?
US Patent 9,216,183 is an issued patent. Its effective life as a patent right is governed by its issue date and standard patent term provisions.
Patent Status and Expiration:
- Issue Date: December 22, 2015.
- Standard Patent Term: In the United States, the term of a utility patent is generally 20 years from the date on which the application for the patent was filed.
- Estimated Expiration Date: Based on the filing date of the application that led to US Patent 9,216,183, the patent is projected to expire. While the precise filing date of the parent application is required for exact calculation, typically such patents are filed several years before their issue date. Assuming a filing date around 2010-2012, the patent would likely expire around 2030-2032.
Note: Patent terms can be extended under certain circumstances, such as through the Patent Term Adjustment (PTA) or Patent Term Extension (PTE) mechanisms, particularly for pharmaceutical patents. These extensions are granted to compensate for delays in patent prosecution or regulatory review. Specific details regarding PTA/PTE for this patent would require further investigation of the USPTO file wrapper.
What are the Potential Commercial Implications for Companies Developing Similar Therapies?
The existence and scope of US Patent 9,216,183 present significant commercial implications for any entity developing or planning to develop therapies targeting lipid oxidation.
Commercial Implications:
- Freedom to Operate (FTO): Companies developing methods for treating diseases involving lipid oxidation using compounds similar to liproxstatin-1 must conduct thorough FTO analyses to ensure they do not infringe on the claims of this patent.
- Licensing Requirements: If a company's proposed therapy falls within the scope of the patent's claims, it may need to secure a license from Northwestern University or its designated licensees to legally market the product.
- Development Strategy: The patent may influence R&D strategies by encouraging the development of compounds with distinct mechanisms of action or by targeting disease indications not explicitly or broadly covered by the patent.
- Market Exclusivity: For Northwestern University and its licensees, the patent provides a period of market exclusivity, preventing competitors from practicing the patented methods without authorization. This exclusivity is crucial for recouping R&D investments.
- Litigation Risk: Infringement of this patent could lead to costly litigation, including injunctions and damages, for any infringing party. Conversely, the patent holder may engage in enforcement actions to protect its intellectual property.
- Valuation for Investment: For investors, the presence of this patent can be a positive indicator of intellectual property strength for the technology but also necessitates an assessment of potential licensing costs or FTO risks for portfolio companies.
The patent's claims regarding the method of treatment for a wide range of oxidative stress-related diseases make it a significant piece of intellectual property in the field of antioxidant therapeutics.
Key Takeaways
- US Patent 9,216,183, issued December 22, 2015, to Northwestern University, covers methods for treating or preventing disease states involving lipid oxidation.
- The core of the patent lies in the administration of liproxstatin-1 or its functional analogs, defined by their ability to inhibit lipid oxidation.
- Targeted disease states are broad, encompassing cardiovascular diseases, neurodegenerative disorders, inflammatory conditions, and metabolic disorders, among others.
- The mechanism of action involves scavenging peroxyl radicals and breaking the chain reaction of lipid peroxidation.
- The patent landscape for lipid oxidation inhibitors is competitive, with numerous existing patents for various antioxidant classes and mechanisms.
- The patent is projected to expire around 2030-2032, subject to potential extensions.
- Commercial implications include the need for FTO analysis, potential licensing requirements, and strategic adjustments for companies developing similar therapies.
FAQs
-
What specific chemical structures are considered "functional analogs" of liproxstatin-1 under this patent?
Functional analogs are defined by their ability to inhibit or reduce lipid oxidation, often through possession of an aminoxyl radical moiety or by structural similarity that enables peroxyl radical scavenging. The patent provides general formulas and examples to delineate this scope.
-
Does this patent cover the sale of liproxstatin-1 as a drug product, or only the method of using it to treat diseases?
This patent primarily claims the method of treating or preventing disease states. While it protects the use of liproxstatin-1 for these specific therapeutic purposes, it does not claim the compound itself as a composition of matter unless that was covered in a separate, granted patent.
-
Can a company develop a different type of antioxidant for treating cardiovascular disease without infringing this patent?
Whether a different antioxidant infringes depends on its mechanism of action and whether it falls within the scope of the claims, particularly the definition of "functional analog" and the method of treating "disease states involving lipid oxidation." A different antioxidant with a completely distinct mechanism might not infringe.
-
What is the projected expiration date of US Patent 9,216,183, and can it be extended?
The patent is projected to expire around 2030-2032 based on a typical 20-year term from filing. Patent Term Adjustment (PTA) or Patent Term Extension (PTE) may apply, potentially extending the term.
-
Are there any approved drugs on the market that utilize the technology claimed in US Patent 9,216,183?
As of the knowledge cut-off, information regarding specific approved drugs directly relying on US Patent 9,216,183 would require a detailed market and regulatory review. The patent describes a method of treatment, and any drug utilizing this method would need to undergo regulatory approval processes.
Citations
[1] Northwestern University. (2015). Method of treating or preventing disease states involving lipid oxidation. U.S. Patent No. 9,216,183. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
